WNT5A and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, the Wnt-5a/β-catenin pathway has been extensively investigated as a key target in cancer treatment and in fine-tuning the regulation of hematopoiesis.39,40 Previous studies were indicated that aberrantly expression and high expression of β-catenin cause to AML and poor prognosis in AML patients, respectively.41,42 Also it was reported that the Wnt/β-catenin pathway activation was detected in samples from patients with CML in blastic crisis.